Biodel Stock Price, News & Analysis (NASDAQ:ALBO)

$24.11 0.65 (2.77 %)
(As of 12/17/2017 10:37 AM ET)
Previous Close$24.11
Today's Range$23.28 - $25.36
52-Week Range$15.31 - $29.20
Volume56,880 shs
Average Volume56,603 shs
Market Capitalization$214.57 million
P/E RatioN/A
Dividend YieldN/A
Beta1.43

About Biodel (NASDAQ:ALBO)

Biodel logoBiodel Inc. is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia. It also develops insulin formulations for Type 1 and Type 2 diabetes patients. Its product pipeline includes RHI-based Ultra-Rapid-Acting Insulin, Analog-based Ultra-Rapid-Acting Insulin, Concentrated Ultra-Rapid-Acting Insulin and Glucagon. The Company's BIOD-531 is a Concentrated Ultra-Rapid-Acting Insulin and its insulin analog-based ultra-rapid-acting insulin product candidates include BIOD-123, BIOD-531, BIOD-238 and BIOD-250. It also conducts pre-clinical testing to develop liquid formulations of glucagon for hypoglycemic rescue and other indications.

Receive ALBO News and Ratings via Email

Sign-up to receive the latest news and ratings for ALBO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Other
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ALBO
CUSIPN/A
Phone857-254-5555

Debt

Debt-to-Equity RatioN/A
Current Ratio7.33%
Quick Ratio7.33%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$11.36 million
Price / Sales18.89
Cash FlowN/A
Price / CashN/A
Book Value$17.06 per share
Price / Book1.41

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees12
Outstanding Shares8,900,000

Biodel (NASDAQ:ALBO) Frequently Asked Questions

What is Biodel's stock symbol?

Biodel trades on the NASDAQ under the ticker symbol "ALBO."

How were Biodel's earnings last quarter?

Biodel Inc. (NASDAQ:ALBO) announced its earnings results on Monday, August, 21st. The biopharmaceutical company reported ($0.86) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.84) by $0.02. View Biodel's Earnings History.

Where is Biodel's stock going? Where will Biodel's stock price be in 2017?

6 brokers have issued 12 month price targets for Biodel's shares. Their forecasts range from $35.00 to $92.00. On average, they anticipate Biodel's stock price to reach $61.67 in the next year. View Analyst Ratings for Biodel.

What are Wall Street analysts saying about Biodel stock?

Here are some recent quotes from research analysts about Biodel stock:

  • 1. Cowen Inc analysts commented, "Albireo reported 3Q earnings today and provided a brief summary of recent progress." (11/17/2017)
  • 2. According to Zacks Investment Research, "Albireo Pharma, Inc. is a biopharmaceutical company. It focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo Pharma Inc., formerly known as BIODEL INC., is based in Boston, United States. " (11/13/2017)
  • 3. Needham & Company LLC analysts commented, "Albireo hosted a KOL meeting yesterday in NYC to discuss Progressive Familial Intrahepatic Cholestasis (PFIC) and provide an update on A4250 clinical program. E. Sturm, investigator in A4250 Phase 2 trial in pediatric cholestasis, highlighted unmet need in PFIC and other rare pediatric cholestasis indications. Biliary diversion surgery is effective option for reducing bile acids in serum, but has 20-40% failure rate. Dr. Sturm is eager for other options and views AB4250 Phase 2 safety and efficacy profile as compelling. Initiation of Phase 3 trial in PFIC1 and PFIC2 patients expected around YE17." (10/26/2017)

Who are some of Biodel's key competitors?

How do I buy Biodel stock?

Shares of Biodel can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biodel's stock price today?

One share of Biodel stock can currently be purchased for approximately $24.11.

How big of a company is Biodel?

Biodel has a market capitalization of $214.57 million and generates $11.36 million in revenue each year. Biodel employs 12 workers across the globe.

How can I contact Biodel?

Biodel's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The biopharmaceutical company can be reached via phone at 857-254-5555 or via email at [email protected]


MarketBeat Community Rating for Biodel (ALBO)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  89 (Vote Outperform)
Underperform Votes:  106 (Vote Underperform)
Total Votes:  195
MarketBeat's community ratings are surveys of what our community members think about Biodel and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Biodel (NASDAQ:ALBO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $61.67$61.67$46.50N/A
Price Target Upside: 137.27% upside137.27% upside99.57% upsideN/A

Biodel (NASDAQ:ALBO) Consensus Price Target History

Price Target History for Biodel (NASDAQ:ALBO)

Biodel (NASDAQ:ALBO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/17/2017CowenReiterated RatingBuyN/AView Rating Details
11/15/2017Roth CapitalInitiated CoverageBuy -> Buy$92.00N/AView Rating Details
10/26/2017Needham & Company LLCReiterated RatingBuyN/AView Rating Details
9/11/2017WedbushReiterated RatingOutperform$58.00LowView Rating Details
2/16/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuyN/AView Rating Details
1/25/2017William BlairInitiated CoverageOutperformN/AView Rating Details
(Data available from 12/17/2015 forward)

Earnings

Biodel (NASDAQ:ALBO) Earnings History and Estimates Chart

Earnings by Quarter for Biodel (NASDAQ:ALBO)

Biodel (NASDAQ ALBO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/21/20176/30/2017($0.84)($0.86)ViewN/AView Earnings Details
5/10/2017Q2 2017($1.11)($1.06)ViewN/AView Earnings Details
8/11/2016Q216($0.05)ViewN/AView Earnings Details
5/9/2016Q2($0.04)($0.09)ViewN/AView Earnings Details
2/16/2016Q1($0.08)($0.05)ViewN/AView Earnings Details
12/17/2015Q315($0.11)($0.05)ViewListenView Earnings Details
8/13/2015Q3($0.10)($0.12)ViewListenView Earnings Details
5/6/2015Q215($0.23)($0.27)ViewN/AView Earnings Details
2/12/2015Q115($0.18)($0.20)ViewN/AView Earnings Details
12/17/2014Q414($0.27)($0.16)ViewN/AView Earnings Details
8/11/2014Q2 2014($0.26)($0.15)ViewN/AView Earnings Details
5/13/2014Q114($0.26)($0.29)ViewN/AView Earnings Details
2/6/2014Q4($0.19)($0.20)ViewN/AView Earnings Details
12/18/2013Q4($0.30)($0.04)ViewListenView Earnings Details
8/12/2013Q3 2013($0.37)($0.66)ViewN/AView Earnings Details
5/8/2013Q2 2013($0.43)($0.37)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Biodel (NASDAQ:ALBO) Earnings Estimates

2017 EPS Consensus Estimate: ($3.34)
2018 EPS Consensus Estimate: ($2.86)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.91)($0.91)($0.91)
Q2 20171($0.87)($0.87)($0.87)
Q3 20172($0.79)($0.76)($0.78)
Q4 20172($0.81)($0.75)($0.78)
Q1 20182($0.76)$0.47($0.15)
Q2 20182($0.98)($0.75)($0.87)
Q3 20182($1.05)($0.76)($0.91)
Q4 20182($1.13)($0.76)($0.95)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Biodel (NASDAQ:ALBO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Biodel (NASDAQ ALBO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 22.30%
Institutional Ownership Percentage: 29.22%
Insider Trades by Quarter for Biodel (NASDAQ:ALBO)

Biodel (NASDAQ ALBO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/1/2017Plc AstrazenecaMajor ShareholderSell500,000$21.40$10,700,000.00View SEC Filing  
12/20/2013Brian Jg PereiraDirectorSell4,734$2.26$10,698.84View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Biodel (NASDAQ ALBO) News Headlines

Source:
DateHeadline
Biodel Inc. to Post FY2017 Earnings of ($3.33) Per Share, Wedbush Forecasts (ALBO)Biodel Inc. to Post FY2017 Earnings of ($3.33) Per Share, Wedbush Forecasts (ALBO)
www.americanbankingnews.com - December 11 at 2:10 AM
Critical Analysis: RegeneRx Biopharmaceuticals (RGRX) and Biodel (ALBO)Critical Analysis: RegeneRx Biopharmaceuticals (RGRX) and Biodel (ALBO)
www.americanbankingnews.com - December 7 at 3:32 AM
Biodel Inc. (ALBO) Major Shareholder Sells $10,700,000.00 in StockBiodel Inc. (ALBO) Major Shareholder Sells $10,700,000.00 in Stock
www.americanbankingnews.com - December 5 at 5:36 PM
 Analysts Anticipate Biodel Inc. (ALBO) to Announce -$0.78 EPS Analysts Anticipate Biodel Inc. (ALBO) to Announce -$0.78 EPS
www.americanbankingnews.com - December 4 at 3:14 PM
RegeneRx Biopharmaceuticals (RGRX) & Biodel (ALBO) Critical ComparisonRegeneRx Biopharmaceuticals (RGRX) & Biodel (ALBO) Critical Comparison
www.americanbankingnews.com - December 4 at 1:28 PM
Analyzing RegeneRx Biopharmaceuticals (RGRX) and Biodel (ALBO)Analyzing RegeneRx Biopharmaceuticals (RGRX) and Biodel (ALBO)
www.americanbankingnews.com - December 1 at 5:40 AM
Financial Comparison: Biodel (ALBO) and RegeneRx Biopharmaceuticals (RGRX)Financial Comparison: Biodel (ALBO) and RegeneRx Biopharmaceuticals (RGRX)
www.americanbankingnews.com - November 27 at 12:15 PM
Comparing Biodel (ALBO) & RegeneRx Biopharmaceuticals (RGRX)Comparing Biodel (ALBO) & RegeneRx Biopharmaceuticals (RGRX)
www.americanbankingnews.com - November 26 at 5:10 AM
Analyzing Biodel (ALBO) and RegeneRx Biopharmaceuticals (RGRX)Analyzing Biodel (ALBO) and RegeneRx Biopharmaceuticals (RGRX)
www.americanbankingnews.com - November 25 at 1:16 PM
Biodel Inc. (ALBO) Receives Consensus Rating of "Buy" from BrokeragesBiodel Inc. (ALBO) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - November 24 at 3:56 AM
Critical Contrast: RegeneRx Biopharmaceuticals (RGRX) & Biodel (ALBO)Critical Contrast: RegeneRx Biopharmaceuticals (RGRX) & Biodel (ALBO)
www.americanbankingnews.com - November 19 at 9:28 AM
Biodel Inc. Expected to Earn FY2017 Earnings of ($3.40) Per Share (ALBO)Biodel Inc. Expected to Earn FY2017 Earnings of ($3.40) Per Share (ALBO)
www.americanbankingnews.com - November 17 at 9:44 PM
Biodel Inc. (ALBO) Stock Rating Reaffirmed by Cowen and CompanyBiodel Inc. (ALBO) Stock Rating Reaffirmed by Cowen and Company
www.americanbankingnews.com - November 17 at 7:58 PM
Zacks: Analysts Anticipate Biodel Inc. (ALBO) to Announce -$0.82 Earnings Per ShareZacks: Analysts Anticipate Biodel Inc. (ALBO) to Announce -$0.82 Earnings Per Share
www.americanbankingnews.com - November 16 at 5:18 AM
Biodel Inc. (ALBO) Coverage Initiated by Analysts at Roth CapitalBiodel Inc. (ALBO) Coverage Initiated by Analysts at Roth Capital
www.americanbankingnews.com - November 15 at 11:41 AM
Albireo Reports Third Quarter 2017 Financial ResultsAlbireo Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 14 at 4:13 PM
Zacks Investment Research Lowers Biodel Inc. (ALBO) to HoldZacks Investment Research Lowers Biodel Inc. (ALBO) to Hold
www.americanbankingnews.com - November 13 at 8:30 PM
Albireo to Present at the Jefferies 2017 London Healthcare ConferenceAlbireo to Present at the Jefferies 2017 London Healthcare Conference
finance.yahoo.com - November 9 at 4:44 PM
Biodel Inc. (ALBO) Receives Average Rating of "Buy" from BrokeragesBiodel Inc. (ALBO) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - October 30 at 1:40 AM
Biodel Inc. (ALBO) Receives "Buy" Rating from Needham & Company LLCBiodel Inc. (ALBO) Receives "Buy" Rating from Needham & Company LLC
www.americanbankingnews.com - October 26 at 11:58 PM
Biodel Inc. (ALBO) Expected to Post Earnings of -$0.85 Per ShareBiodel Inc. (ALBO) Expected to Post Earnings of -$0.85 Per Share
www.americanbankingnews.com - October 26 at 9:18 PM
Biodel Inc. (ALBO) Rating Increased to Buy at Zacks Investment ResearchBiodel Inc. (ALBO) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - October 25 at 6:32 PM
Featured Company News - Albireo Pharma to Present Final Results of Phase-2 Study of A4250 in Children with Cholestatic Liver Disease at The Liver Meeting(R) 2017Featured Company News - Albireo Pharma to Present Final Results of Phase-2 Study of A4250 in Children with Cholestatic Liver Disease at The Liver Meeting(R) 2017
finance.yahoo.com - October 24 at 4:54 PM
Biodel Inc. (ALBO) Stock Rating Reaffirmed by WedbushBiodel Inc. (ALBO) Stock Rating Reaffirmed by Wedbush
www.americanbankingnews.com - October 24 at 8:29 AM
Final Results of Albireo’s Phase 2 Study of A4250 in Children with Cholestatic Liver Disease Presented at The Liver Meeting® 2017Final Results of Albireo’s Phase 2 Study of A4250 in Children with Cholestatic Liver Disease Presented at The Liver Meeting® 2017
finance.yahoo.com - October 20 at 5:32 PM
Albireo to Host KOL Event on Progressive Familial Intrahepatic CholestasisAlbireo to Host KOL Event on Progressive Familial Intrahepatic Cholestasis
finance.yahoo.com - October 16 at 4:37 PM
Biodel Inc. (ALBO) Expected to Announce Earnings of -$0.85 Per ShareBiodel Inc. (ALBO) Expected to Announce Earnings of -$0.85 Per Share
www.americanbankingnews.com - October 7 at 8:24 PM
Biodel Inc. (ALBO) Given Average Rating of "Buy" by BrokeragesBiodel Inc. (ALBO) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 5 at 2:32 AM
Final Results of Albireo’s Phase 2 Study of A4250 in Children with Cholestatic Liver Disease to be Presented at The Liver Meeting® 2017Final Results of Albireo’s Phase 2 Study of A4250 in Children with Cholestatic Liver Disease to be Presented at The Liver Meeting® 2017
finance.yahoo.com - October 3 at 3:26 PM
Albireo to Present at Investor Conferences in SeptemberAlbireo to Present at Investor Conferences in September
finance.yahoo.com - September 19 at 3:44 PM
-$0.85 EPS Expected for Biodel Inc. (ALBO) This Quarter-$0.85 EPS Expected for Biodel Inc. (ALBO) This Quarter
www.americanbankingnews.com - September 19 at 2:18 AM
Albireo Pharma (ALBO) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - SlideshowAlbireo Pharma (ALBO) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 14 at 4:14 PM
Biodel Inc. (ALBO) to Post Q3 2017 Earnings of ($0.76) Per Share, Wedbush ForecastsBiodel Inc. (ALBO) to Post Q3 2017 Earnings of ($0.76) Per Share, Wedbush Forecasts
www.americanbankingnews.com - September 14 at 7:27 AM
Biodel Inc. (ALBO) to Post FY2020 Earnings of ($3.25) Per Share, Wedbush ForecastsBiodel Inc. (ALBO) to Post FY2020 Earnings of ($3.25) Per Share, Wedbush Forecasts
www.americanbankingnews.com - September 13 at 4:02 PM
Biodel Inc. (ALBO) Rating Reiterated by WedbushBiodel Inc. (ALBO) Rating Reiterated by Wedbush
www.americanbankingnews.com - September 11 at 9:32 PM
Albireo to Present at 19th Annual Rodman & Renshaw Global Investment ConferenceAlbireo to Present at 19th Annual Rodman & Renshaw Global Investment Conference
finance.yahoo.com - September 5 at 5:09 PM
Q3 2017 Earnings Forecast for Biodel Inc. (ALBO) Issued By William BlairQ3 2017 Earnings Forecast for Biodel Inc. (ALBO) Issued By William Blair
www.americanbankingnews.com - August 23 at 8:22 AM
Biodel Inc. (ALBO) Releases Quarterly  Earnings Results, Misses Expectations By $0.02 EPSBiodel Inc. (ALBO) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - August 22 at 10:31 AM
Albireo Reports Second Quarter 2017 Financial ResultsAlbireo Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 21 at 3:51 PM
Biodel Inc. (ALBO) Coverage Initiated by Analysts at Cowen and CompanyBiodel Inc. (ALBO) Coverage Initiated by Analysts at Cowen and Company
www.americanbankingnews.com - August 20 at 11:58 PM
Biodel Inc. (ALBO) Given Consensus Recommendation of "Buy" by AnalystsBiodel Inc. (ALBO) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - August 16 at 10:54 AM
 Brokerages Anticipate Biodel Inc. (ALBO) Will Post Earnings of -$0.83 Per Share Brokerages Anticipate Biodel Inc. (ALBO) Will Post Earnings of -$0.83 Per Share
www.americanbankingnews.com - August 13 at 4:16 AM
Albireo to Present at Wedbush PacGrow Healthcare ConferenceAlbireo to Present at Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 8 at 3:38 PM
Whats in the Cards for Humana (HUM) this Earnings Season?What's in the Cards for Humana (HUM) this Earnings Season?
www.nasdaq.com - July 31 at 3:50 PM
Whats in the Cards for Merrimack (MACK) in Q2 Earnings?What's in the Cards for Merrimack (MACK) in Q2 Earnings?
www.nasdaq.com - July 28 at 4:19 PM
Endo International PLC (ENDP) and Biodel (NASDAQ:ALBO) Financial ReviewEndo International PLC (ENDP) and Biodel (NASDAQ:ALBO) Financial Review
www.americanbankingnews.com - July 16 at 2:11 PM
Comparing Biodel (NASDAQ:ALBO) & Endo International PLC (ENDP)Comparing Biodel (NASDAQ:ALBO) & Endo International PLC (ENDP)
www.americanbankingnews.com - July 7 at 8:28 PM
Biodel (ALBO) & Endo International PLC (ENDP) Financial ComparisonBiodel (ALBO) & Endo International PLC (ENDP) Financial Comparison
www.americanbankingnews.com - July 6 at 12:32 AM
Research Analysts Set Expectations for Biodel Inc.s FY2017 Earnings (NASDAQ:ALBO)Research Analysts Set Expectations for Biodel Inc.'s FY2017 Earnings (NASDAQ:ALBO)
www.americanbankingnews.com - July 3 at 8:34 AM
Biodel Inc. (NASDAQ:ALBO) Receives New Coverage from Analysts at WedbushBiodel Inc. (NASDAQ:ALBO) Receives New Coverage from Analysts at Wedbush
www.americanbankingnews.com - July 1 at 12:02 PM

SEC Filings

Biodel (NASDAQ:ALBO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Biodel (NASDAQ:ALBO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Biodel (NASDAQ ALBO) Stock Chart for Sunday, December, 17, 2017

Loading chart…

This page was last updated on 12/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.